KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $26.43 Average Price Target from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $26.4286.

Several equities analysts recently commented on KALV shares. Leerink Partners increased their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, July 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. JMP Securities increased their target price on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Finally, HC Wainwright increased their target price on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, July 8th.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,294 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $15.84, for a total value of $115,536.96. Following the sale, the chief executive officer owned 395,189 shares of the company’s stock, valued at $6,259,793.76. This trade represents a 1.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul K. Audhya sold 2,336 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $13.42, for a total transaction of $31,349.12. Following the completion of the sale, the insider directly owned 122,505 shares in the company, valued at approximately $1,644,017.10. This trade represents a 1.87% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 26,856 shares of company stock worth $374,910. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Earned Wealth Advisors LLC bought a new stake in KalVista Pharmaceuticals in the 1st quarter worth $44,000. BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the period. GAMMA Investing LLC lifted its position in shares of KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after purchasing an additional 3,767 shares during the period. CWM LLC lifted its position in shares of KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after purchasing an additional 4,549 shares during the period. Finally, Virtus Investment Advisers LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter worth about $81,000.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $11.50 on Wednesday. The company’s fifty day moving average price is $13.12 and its 200-day moving average price is $12.87. The firm has a market capitalization of $581.01 million, a price-to-earnings ratio of -2.92 and a beta of -0.15. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.21). The firm had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.97 million. As a group, equities research analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).